CERK and breast carcinoma: Moreover, our finding that ET-resistant cancer cells are dependent on CERK, and its product C1P, to maintain low levels of ceramides, and promote cell survival, indicates a new therapeutic target for ET-resistant breast cancer with the potential to improve outcomes for women with ET-resistant disease.